Galapagos Unveils Promising CAR-T Data at EHA 2025

Galapagos ( (GLPG) ) just unveiled an announcement.

On June 12, 2025, Galapagos NV announced new data from its ATALANTA-1 Phase 1/2 study of the investigational CD19 CAR T-cell therapy, GLPG5101, presented at the European Hematology Association Congress. The study demonstrated low toxicity and rapid delivery of fresh, early-memory-enriched CAR-T cells in relapsed refractory non-Hodgkin’s Lymphoma patients, with a significantly low 5% attrition rate. The decentralized manufacturing approach allows for a median vein-to-vein time of seven days, potentially expanding access to CAR-T therapy and improving safety outcomes.

The most recent analyst rating on (GLPG) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.

Spark’s Take on GLPG Stock

According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.

Galapagos’s overall stock score is driven by its financial stability and strong cash reserves, offset by significant profitability and cash flow challenges. Technical indicators show a mildly positive trend, while valuation remains unattractive due to negative earnings. The earnings call highlights strategic initiatives and a robust pipeline, but high restructuring costs and expected cash burn are notable risks.

To see Spark’s full report on GLPG stock, click here.

More about Galapagos

Galapagos is a biotechnology company operating in Europe, the U.S., and Asia, focused on transforming patient outcomes through innovative science. The company addresses high unmet medical needs by developing a pipeline of best-in-class medicines, utilizing a decentralized cell therapy manufacturing platform to enhance patient experience and outcomes.

Average Trading Volume: 359,557

Technical Sentiment Signal: Sell

Current Market Cap: $1.89B

See more data about GLPG stock on TipRanks’ Stock Analysis page.